NR4A3 and bladder transitional cell carcinoma: Although direct activators of NR4A3 are not currently available, potential future approaches may include: (1) using ER stress inducers to amplify NR4A3‘s pro-apoptotic effects; (2) developing gene therapy strategies to restore or enhance NR4A3 expression; and (3) evaluating NR4A3 as a prognostic biomarker in larger BLCA patient cohorts to support its clinical application.